Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in...

Area of Science:

• Bone Biology
• Molecular Signaling
• Genomics

Background:

• Beta-arrestin2 interacts with activated parathyroid hormone (PTH)/PTHrP receptors, modulating G protein and MAPK signaling pathways.
• The absence of beta-arrestin2 alters the effects of intermittent and continuous PTH on bone.
• Understanding beta-arrestin2's role is crucial for elucidating PTH's complex actions on bone metabolism.

Purpose of the Study:

• To identify bone genes regulated by PTH and beta-arrestin2.
• To investigate the molecular mechanisms by which beta-arrestin2 influences PTH signaling in osteoblasts.

Main Methods:

• Microarray analysis of primary osteoblastic cells from wild-type and beta-arrestin2-deficient mice.
• Gene expression profiling after exposure to intermittent PTH, continuous PTH, or vehicle for two weeks.
• Pathway analysis to identify key signaling networks involved.

Main Results:

• Intermittent PTH specifically up-regulated 215 and down-regulated 200 gene sequences in wild-type cells, with beta-arrestin2 controlling approximately two-thirds of these.
• Beta-arrestin2 is essential for down-regulating small leucine-rich proteoglycans (SLRPs), including osteoglycin, osteomodulin, and asporin.
• A major gene network centered on p38 MAPK and NFkappaB requires beta-arrestin2 for PTH-mediated regulation, while a TGFB1-centered network is normally repressed by beta-arrestin2.
• Known PTH targets regulated by the cAMP/PKA pathway were unaffected by beta-arrestin2.

Conclusions:

• Beta-arrestin2 plays a significant role in mediating the effects of intermittent PTH on osteoblasts, primarily through p38 MAPK and NFkappaB signaling pathways.
• These findings reveal novel molecular mechanisms underlying both the anabolic and catabolic effects of PTH on bone.
• Beta-arrestin2's regulation of specific gene networks provides new insights into bone remodeling and potential therapeutic targets.